Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 3/20 | 0.68 |
| ▸ | FEN1 | P39748 | 3/20 | 0.68 |
| ▸ | MMP1 | P03956 | 2/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23485908 | 0.88 | ALDH1A1 (0.58) | ERCC5FEN1MMP1PARP10RAB9A | |
| SCHEMBL24209475 | 0.86 | MMP13 (0.57) | ERCC5FEN1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17336641 | 0.85 | ERCC5 (0.70) | ERCC5FEN1PARP10SMN1; SMN2POLB | |
| SCHEMBL5753439 | 0.85 | ERCC5 (0.62) | ERCC5FEN1MMP1PARP10SRD5A2 | |
| SCHEMBL275775 | 0.85 | KMT2A (0.67) | ERCC5FEN1SMN1; SMN2HPGDPOLB | |
| SCHEMBL24209360 | 0.85 | KMT2A (0.50) | ERCC5FEN1MMP1SRD5A2SMN1; SMN2 | |
| SCHEMBL23485764 | 0.85 | KMT2A (0.54) | ERCC5FEN1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL24209522 | 0.85 | MMP1 (0.59) | ERCC5FEN1MMP1SMN1; SMN2HPGD | |
| SCHEMBL29169327 | 0.84 | ERCC5 (0.70) | ERCC5FEN1MMP1PARP10SRD5A2 | |
| SCHEMBL10844824 | 0.84 | MMP1 (0.60) | ERCC5FEN1MMP1PARP10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552798-B2 | Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors | HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| CN-118164864-A | Luo Shasi and process for the preparation of intermediates therefor | 北京海美源医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114761399-B | Imidazole carboxamide derivatives as bruton's tyrosine kinase inhibitors | 河南知微生物医药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116018138-A | Substituted 1H-imidazo [1,2-b ] pyrazole-3-carboxamides as inhibitors of brunauer tyrosine kinase | 河南知微生物医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| CN-114761399-A | Imidazole carboxamide derivatives as Bruton's tyrosine kinase inhibitors | 河南知微生物医药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-111499572-B | Preparation method of intermediate of roxasistat | 安徽省庆云医药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022012550-A1 | SUBSTITUTED 1H-IMIDAZO [1, 2-B] PYRAZOLE-3-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN NORMAL UNIVERSITY (CN) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021110142-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN NORMAL UNIVERSITY (CN) | 2021-06-10 | — | — | WO | disclosed |
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-10 | — | — | US | disclosed |
| US-7589214-B2 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589214-B2 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589214-B2 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101460466-A | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2009-06-17 | — | — | CN | disclosed |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-27 | — | — | US | disclosed |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-27 | — | — | US | disclosed |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-27 | — | — | US | disclosed |
| WO-2007117692-A2 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K1, MAP3K20 | ERCC5 3188/4885FEN1 3152/4885MMP1 4335/4885 |
| US-12552798-B2 | Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors | BTK, LCK, SYK | ERCC5 1829/4885FEN1 1603/4885MMP1 3014/4885 |
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | BTK, SYK, LYN | ERCC5 485/4885FEN1 1750/4885MMP1 3491/4885 |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | PDXK, PRKACA, PRKACB | ERCC5 3882/4885FEN1 3776/4885MMP1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.